.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BX17_Carfloglitazar.Carfloglitazar .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BX17_Carfloglitazar.Carfloglitazar| name: | Carfloglitazar |
| ATC code: | A10BX17 | route: | orally |
| n-compartments | 1 |
Carfloglitazar is a dual PPAR alpha and gamma agonist developed for the treatment of type 2 diabetes mellitus. It works by improving insulin sensitivity and modulating lipid metabolism. As of 2024, carfloglitazar is not an approved or marketed drug and was primarily investigated in early-phase clinical trials.
No published clinical pharmacokinetic studies are available for carfloglitazar in humans. The following parameters are estimated based on typical values for drugs in this class (PPAR agonists) and preclinical information.